Pancreatic Cancer Clinical Trials in Chicago, Illinois

7 studies are recruiting for pancreatic cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope, Chicago, Illinois

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. CREO - Microwave Ablation Feasibility Study

   The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment w…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   7 in total

   Run by

   Banner Health

   See if you can join NCT07817147 on ClinicalTrials.gov

3. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Hospital, Chicago, Illinois

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

5. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago, Illinois

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

6. Lidocaine Infusion in Pancreatic Cancer

   This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Illnois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT04048278 on ClinicalTrials.gov

7. Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

   Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rush University Cancer Center, Chicago, Illinois

   Locations

   6 in total

   Run by

   CivaTech Oncology

   See if you can join NCT02843945 on ClinicalTrials.gov